Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of August 5, 2026, PLX trades at $2.37 with a market cap of $186.93M and a P/E ratio of 11.82. PLX moved +2.16% today. Year to date, PLX is +31.67%; over the trailing twelve months it is +58.00%. Its 52-week range spans $1.32 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Protalix BioTherapeutics, Inc. Common Stock (PLX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. PLX moved +2.16% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $2.37 |
| Market Cap | $186.93M |
| P/E Ratio | 11.82 |
| EPS | $0.20 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.19 |
| 52-Week Low | $1.32 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $76.38M |
| Net Income | $15.33M |
| Gross Margin | 69.97% |
1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.